Anti‐CD19 CAR T‐cell therapies approved or under investigation in relapsed/refractory large B‐cell lymphoma
| Therapy . | Axicabtagene ciloleucel(Yescarta) [22] . | Tisagenlecleucel(Kymriah) [26] . | Lisocabtagene ciloleucel [29] . |
|---|---|---|---|
| Patient population | Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B‐cell lymphoma, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma | Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma | Under investigation in patients with DLBCL after two or more lines of therapy, including DLBCL not otherwise specified (de novo or transformed follicular lymphoma) and high‐grade B‐cell lymphoma (double‐/triple‐hit) |
| CAR | Anti‐CD19 scFV, CD28 costimulatory domain, CD3ζ activation domain | Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain | Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain; manufactured in a 1:1 ratio of CD4:CD8 T cells |
| Pivotal trial | ZUMA‐1 [12, 18] (NCT02348216) | JULIET [28] (NCT02445248) | TRANSCEND NHL 001 [29] (NCT02631044) |
| Therapy . | Axicabtagene ciloleucel(Yescarta) [22] . | Tisagenlecleucel(Kymriah) [26] . | Lisocabtagene ciloleucel [29] . |
|---|---|---|---|
| Patient population | Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B‐cell lymphoma, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma | Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma | Under investigation in patients with DLBCL after two or more lines of therapy, including DLBCL not otherwise specified (de novo or transformed follicular lymphoma) and high‐grade B‐cell lymphoma (double‐/triple‐hit) |
| CAR | Anti‐CD19 scFV, CD28 costimulatory domain, CD3ζ activation domain | Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain | Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain; manufactured in a 1:1 ratio of CD4:CD8 T cells |
| Pivotal trial | ZUMA‐1 [12, 18] (NCT02348216) | JULIET [28] (NCT02445248) | TRANSCEND NHL 001 [29] (NCT02631044) |
Abbreviations: CAR, chimeric antigen receptor; DLBCL, diffuse large B‐cell lymphoma; scFV, single‐chain variable fragment.
Anti‐CD19 CAR T‐cell therapies approved or under investigation in relapsed/refractory large B‐cell lymphoma
| Therapy . | Axicabtagene ciloleucel(Yescarta) [22] . | Tisagenlecleucel(Kymriah) [26] . | Lisocabtagene ciloleucel [29] . |
|---|---|---|---|
| Patient population | Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B‐cell lymphoma, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma | Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma | Under investigation in patients with DLBCL after two or more lines of therapy, including DLBCL not otherwise specified (de novo or transformed follicular lymphoma) and high‐grade B‐cell lymphoma (double‐/triple‐hit) |
| CAR | Anti‐CD19 scFV, CD28 costimulatory domain, CD3ζ activation domain | Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain | Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain; manufactured in a 1:1 ratio of CD4:CD8 T cells |
| Pivotal trial | ZUMA‐1 [12, 18] (NCT02348216) | JULIET [28] (NCT02445248) | TRANSCEND NHL 001 [29] (NCT02631044) |
| Therapy . | Axicabtagene ciloleucel(Yescarta) [22] . | Tisagenlecleucel(Kymriah) [26] . | Lisocabtagene ciloleucel [29] . |
|---|---|---|---|
| Patient population | Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B‐cell lymphoma, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma | Approved for the treatment of adult patients with relapsed or refractory large B‐cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, high‐grade B‐cell lymphoma, and DLBCL arising from follicular lymphoma | Under investigation in patients with DLBCL after two or more lines of therapy, including DLBCL not otherwise specified (de novo or transformed follicular lymphoma) and high‐grade B‐cell lymphoma (double‐/triple‐hit) |
| CAR | Anti‐CD19 scFV, CD28 costimulatory domain, CD3ζ activation domain | Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain | Anti‐CD19 scFV, 4‐1BB costimulatory domain, CD3ζ activation domain; manufactured in a 1:1 ratio of CD4:CD8 T cells |
| Pivotal trial | ZUMA‐1 [12, 18] (NCT02348216) | JULIET [28] (NCT02445248) | TRANSCEND NHL 001 [29] (NCT02631044) |
Abbreviations: CAR, chimeric antigen receptor; DLBCL, diffuse large B‐cell lymphoma; scFV, single‐chain variable fragment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
